Sodium Benzoate as a Promising Treatment for Amnestic Mild Cognitive Impairment: Evidence from a Randomized Controlled Trial

Highlight

– Sodium benzoate, a D-amino acid oxidase (DAO) inhibitor, significantly improved short-term memory in patients with amnestic mild cognitive impairment (aMCI).
– The study was a randomized, double-blind, placebo-controlled trial over 24 weeks involving 82 aMCI patients.
– Overall cognitive improvement showed a positive trend but did not reach statistical significance.
– Sodium benzoate was well tolerated without additional adverse effects compared to placebo.
– The ‘recall of test instructions’ item of ADAS-cog may be a sensitive measure for memory improvements in aMCI.

Study Background and Disease Burden